SAR-439459

N/A

Report date: 2025/04/22 15:33:30

Base Information

Drug NameSAR-439459
Drug Alias NameSAR439459SAR-439459
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTransforming growth factor beta inhibitors
TargetsTransforming growth factor beta
Therapy Area/IndicationsSolid tumoursOsteogenesis ImperfectaLiver Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofiSanofi (China) Investment Co Ltd
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsSolid tumoursLiver NeoplasmsMultiple Myeloma
Inactive IndicationsOsteogenesis Imperfecta

Other Information

ATC CodeN/A
Related LinksN/A